Tumors are made of evolving and heterogeneous populations of cells which arise from successive appearance and expansion of subclonal populations, following acquisitions of mutations conferring them a selective advantage. Those subclonal populations can be sensitive or resistant to different treatments, and provide information about tumor aetiology and future evolution. Hence, it is important to be able to assess the level of heterogeneity of tumors with high reliability for clinical applications.
Introduction
Cancer is characterized by the presence of cells growing and dividing without proper control. In the 1970s, Nowell and colleagues suggested that tumor cells follow evolutionary principles, as any other biological population able to acquire heritable transformations. This evolutionary framework has proven very useful in deepening our understanding of cancer aetiology (1) . Currently, evolutionarybased therapies are being developed (2) , for instance to maintain tumors in an "idle state" or to force them into a drug-sensitive state (3, 4) .
A consequence of this progressive accumulation of mutations is intra-tumor heterogeneity. Indeed, when a new mutation occurs in a tumor cell and provides an evolutionary advantage, this cell tends to divide at a higher rate and can seed a new clonal population (5) . This new clone may supersede the whole tumor population, or coexist along it. This process results in a tumor made of a mosaic of clones. Next generation sequencing (NGS), in particular whole exome and whole genome sequencing (WES, WGS), can provide new insights into the heterogeneity and evolution of tumors.
Indeed, early mutations shared among all cancer cells should be detected in more sequencing reads than mutations acquired later by only a fraction of the tumor cells. Thus it may be possible to estimate the intra-tumor heterogeneity (ITH) and reconstruct the clonal history of tumors from WES or WGS data, as reviewed by (5) (6) (7) , and many computational methods have been developed for that purpose (8) (9) (10) (11) . We collectively refer to these methods as "ITH methods" in the following.
Subclonal reconstruction from single cell sequencing has emerged as a new field, simplifying part of the inference problem, but raising the issue of availability for large cohorts (5, (12) (13) (14) .
Previous studies have reported that a large proportion of tumors are heterogeneous (3, (15) (16) (17) , with various consequences for the patient. In particular, high ITH has been associated with treatment resistance and poor prognosis (18) . However, those results rely mostly on very detailed case studies involving only a small number of patients, with favorable experimental settings such as high coverage targeted sequencing on top of NGS, multiple sample collection (multi-site or longitudinal studies) (19) (20) (21) (22) (23) (24) or even single-cell sequencing (25, 26) . In the perspective of large-scale application in a clinical context, one needs to consider more accessible data with respect to cost and invasiveness for the patient, like moderate coverage WES on one sample per patient. A precise evaluation of existing ITH methods in this setting is needed to determine whether they allow us to find distinguishable patterns of heterogeneity and evolution of clinical relevance. Several large scale analyses have attempted to depict the evolutionary landscape of ITH in several cancer types (1) , and to assess the prognostic power of ITH (15, 16, 27) in this setting. In particular, three studies on data from the cancer genome atlas (TCGA) exhibit contradictory results on some cancer types (15, 16, 27) . Indeed, among the 9 cancer types where a significant association between ITH and overall survival was found in at least one study (BRCA, KIRC, LGG, PRAD, GBM, HNSC, OV, UCEC, COAD), 5 were considered in another study with no significant result. In other cancer types, 2 studies consistently found no significant results for 3 types (BLCA, LUSC, STAD), and all 3 studies found no significant results for LUAD and SKCM. A possible explanation for this discrepancy is that the studies base their analyses on different computational pipelines, from variant calling to ITH estimation, leading to different and sometimes contradictory results (27) .
To clarify the robustness and consistency of different ITH methods, we perform a systematic benchmark of 14 computational pipelines for ITH estimates from a single WES sample per patient (combining 2 ways to call mutations with 7 ITH methods), using data from 1,758 patients with three types of cancer from the TCGA database. We show that most existing ITH methods are very sensitive to the choice of mutations called, and that they can give very inconsistent results between each other. We highlight in particular that some methods are influenced by confounding factors such as tumor purity or mutation load. Finally, we show that although ITH measured by some computational pipelines have a weak prognostic power on some cancer types, the prognosis signal is not robust across methods and cancer types, and is confounded with informations available in standard clinical data. As a conclusion, we suggest that results of ITH analysis from single sample WES data with current computational pipelines should be manipulated with caution, and that more robust methods or protocols are likely to be needed for clinical applications.
we extracted 5 features to characterize ITH in a sample: the number of clones, the proportion of SNVs that belong the the major clone, the minimal cellular prevalence of a subclone, the Shannon index of the clonal distribution, and the cellular prevalence of the largest clone in terms of number of SNVs.
Baseline ITH method. To compare results from published ITH methods, we included in the analyses a simple ITH method developed in-house. It performs peak detection on a smoothed histogram of SNVs cellular prevalence (CP). CP is obtained from measured VAF with the following operation
with p the purity (tumor fraction in the sample) estimated by ASCAT, CN normal the copy number of infiltrating non-tumor cells (set to 2); CN tumor total and CN tumor mut the total and mutated copy number in the tumor at the SNV location. In practice, for WES, SNV phasing is not possible, so the minor copy number from ASCAT output was used as CN tumor mut , except for LOH regions where the total was used.
We then estimate a smoothed version of the empirical distribution of CPs using the seaborn function kdeplot, which performs a nonparametric kernel density estimation from package statsmodels with default parameters (Gaussian kernel, with bandwidth estimated with Scott's rules). We finally use the package peakutils to detect peak from the smoothed density. Peak detection was also executed on the first two derivatives of the smoothed density to detect "elbows" in the distribution as well, as they may be subclonal populations with close VAF.
• We kept numerical variables available for every patient • In addition, we only kept the variables (if numerical) or the levels (categorical) which were significantly associated with overall survival by single-variable cox model (package lifelines)
after correction.
Supplementary tables 3, 4, and 5 summarize the clinical variables retained for each cancer type.
Survival regression.
Model. To estimate the prognosis power of a set of features, we use a survival SVM model (39) .
Survival SVM maximizes a concave relaxation of the concordance between the predicted survival ranks and the original observed survival, regularized by a Euclidean norm penalty. Formally, given a training set of n patients with survival information ( 
where P = {(i, j) ∈ [1, n] 2 | y i ≥ y j ∧ δ j = 1} is the set of pairs of patients (i, j) which are comparable, that is, for which we are certain that patient i lived longer than patient j. Intuitively, the loss penalizes the cases where patient i survives longer than patient j but the opposite is predicted by the model. For all computations, we used the function FastSurvivalSVM in the Python Package scikit-survival (40) (41) (42) , with default parameters. The model was trained and tested using a 5-fold cross-validation procedure.
Evaluation procedure. To assess the accuracy of a survival regression model, we use the concordance index (CI) between the predicted score and the true survival information on a cohort with survival information. Given such a cohort (x i , y i , δ i ) i=1,...,n , the CI measures how concordant the predicted survival times s i = f (x i ) are with the observed survival times y i for comparable pairs of patients:
In practice, we compute an approximation of CI with the function concordance.index from the R package survcomp (43, 44) , using the noether method (45) , and the associated one-sided test to compare CI to 0.5, which is the mean CI obtained with a random predictor. Supplementary Table 6 . For analysis purposes, we are using the complementary to the maximal value in the cohort so that the content in immune cells varies in the same direction as tumor purity and remains a positive quantity. We denote those new variables with the prefix inv, e.g., for patient i in the BRCA cohort we define
where T_cells i represents the signature for T cells estimated as explained above.
Results
Assessing ITH on TCGA samples. We collected somatic mutation information from We assess ITH in each sample using 7 representative computational methods: PyClone (8), SciClone (9), PhyloWGS (10) EXPANDS (11), the mutant-allele tumor heterogeneity (MATH) score (37), a custom baseline method based on peak detection on the cellular prevalence histogram (see Methods), and CSR (17), a method providing a consensus of all of the above results (except MATH which is not compatible, see Methods). Table 1 summarizes some important properties of the different methods, which might be helpful for designing future studies and selecting the appropriate tool. All methods but MATH take as input the CNA information in addition to a set of somatic mutation VAFs. PyClone and PhyloWGS also take purity as input. All input has to be pre-computed by third-party approaches. While MATH is a single quantitative measure of ITH based on differences in the mutant-allele fractions among mutated loci, all 6 other methods produce more details such as the number of subclones and their respective proportions in the tumor. In particular, PhyloWGS outputs a lineage tree connecting the subclones.
We tested each method twice on each sample for the two mutation sets. We observed that some methods failed to produce an output on some samples, for different reasons (see success rate for each method in Table 1 ). EXPANDS produces an error for 30% of the samples, mostly for tumors with high purity or very few CNAs. SciClone fails to provide an output for samples with an insufficient number of SNV in regions without CNA or LOH event. PyClone and PhyloWGS non completion cases were caused by a too long runtime. As shown in Figure 1 , there is little overlap between the 207 BLCA (n=351) Intersection of successful runs among the 5 considered ITH methods. The upper venn diagrams concern runs with the public input SNV set, the second line with the protected, and the third the overall intersection, as results with both sets are necessary for a proper and rigorous comparison.
In addition to failures, we observed that the runtime varies significantly between methods ( Table 1) . Figure 2 , the run time of different ITH methods increases with the number of somatic mutations. PyClone and PhyloWGS runtime rises very quickly with the number of mutations in tumor sample, which can be a limitation for applications to heavily mutated tumors.
As shown on
Methods quantifying ITH exhibit inconsistent results. As a first evaluation of ITH methods in the absence of ground truth, we assess the agreement between methods, with a focus on the number of clones. Each method except MATH outputs an estimated number S of subclonal populations, ranging from S = 1 for an homogeneous, clonal tumor to any positive number for an heterogeneous one. Figure 3 presents the distribution of estimated clonality among all samples for each approach and each SNV set. We observe large differences between methods, as well as between SNV sets:
for instance, over all samples, the percentage of estimated clonal tumors (S = 1) varies from 4% (for PhyloWGS on protected data) to 57 % (for PyClone on public data). Moreover, the number of estimated populations can vary strikingly with the mutation set used. There is a clear trend Another way to compare methods is to consider correlations (Pearson's r) between the estimated numbers of populations. This allows us to include the MATH score in the evaluation, considering it as an increasing function of heterogeneity just like the number of populations. In addition, we add to the comparison 5 measures directly extracted from the NGS analysis, namely, the number of mutations in the protected and in the public sets, the percentage of non-diploid cells (estimated by ASCAT), the purity (estimated by ASCAT), and the inv_T _cell (estimated from gene expression signatures). Results are presented in Figure 4 .
Although a clear and consistent message is hard to extract, a few general trends seem to emerge.
First, there is a tendency of results to be more similar for different methods with the same input mutation set, in particular for BRCA. Second, we observe two groups of methods that remain more similar across all three cancer types: EXPANDS, baseline and MATH score on the one hand, and PhyloWGS, PyClone, SciClone on the other hand. The consensus CSR seems to be in the latter group, indicating that it might not fully achieve an equilibrium among the different ITH methods. Previous studies have reported a correlation between MATH score and CNA abundance (27, 49, 50) , or between purity and ITH, as ITH methods were initially designed to refine purity estimation (51, 52) , and we observe similar behaviors. Association with immune infiltration has also been considered (50), though it is worth noting that immune infiltration and tumor purity are not independent, as immune cells are not cancerous. Each group of ITH methods is highly correlated to distinct genomic metrics, mutation load and CNV abundance (perc_non_diploid)
for the first group, and purity (and the opposite of immune cells infiltration (inv_T_cells)) for the latter. This might be indicative of systematic biases in the different methods, rather than biological strong signal as previously reported. Indeed, the strength and direction of all correlations varies between the two groups of ITH methods, and is hence hardly reliable or interpretable in terms of treatment response prediction without more data. Fig. 4 . Correlation between various measures of ITH (MATH score, and number of subclones for the other methods), and other potential confounding variables measured using WES and trancriptomics data. Row and color label represent the method used, with white for the genomic measures not involving ITH. Hatches correspond to public mutation sets. Heatmap colors represent the value of the Pearson's r. We can observe clustering tendencies stable across the 3 cancer types. One of them is highlighted in black lines.
ITH is a weak and non robust prognosis factor.
To test the prognostic power of each ITH quantification method, we collected survival information for the 793 patients on which all ITH methods ran successfully, and assessed how each ITH method allows to predict survival. Since all ITH methods except MATH output several features related to ITH, we did not test each feature individually but instead estimated a combined score for each method with a survival SVM model (see Methods).
More precisely, we extract 5 features from each ITH method: the number of subclonal populations, and four other metrics that allow to distinguish several evolutionary patterns, like early (star-like evolution) or late (tree with a long trunk) clonal diversification (see Methods). We evaluate the performance of each score by 5-fold cross-validation, and prognostic power is assessed on the test fold by computing the concordance index between the SVM prediction and the true patient survival.
For MATH, a single feature is computed, so this procedure simply evaluates the concordance index of the MATH score with survival. In addition, we consider a model where all features of all methods (i.e., a total of 6 × 5 + 1 = 26 features) are combined together. Figure 5 shows the results for each cancer type, each method, and each set of mutations used.
Overall, we observe at least one method achieving significant survival prediction in each cancer type. The combined model is significantly prognostic with both protected and public sets in BLCA and HNSC, but not in BRCA. Among the three cancer types, in the best case, however, the median concordance index on the test sets is barely reaches 0.6 which remains modest for any clinical use.
This suggests that there may be a weak prognostic signal captured by ITH measurement, but it can not be observed consistently with a single method and a single variant calling pipeline in the three cancer types, illustrating the frailty of obtained results. The combined model seems to be a robust alternative, as when it is significant, it has a concordance index in the range of the best performing single method; however the case of BRCA seems particular, as many methods perform worse than random.
Some authors (4, 16) have suggested a non-linear relation between survival and ITH, as very high ITH might be damaging for the tumor, while moderate ITH would be associated with aggressive tumors and prone to treatment resistance. To test this hypothesis in our framework we added squared features to the survival model, allowing second order polynomial relations between ITH and survival. However, this did not significantly impact the results (Supplementary Figure 7) .
Indeed, after multiple test correction, only Expands with the protected mutation set in BRCA prognostic power is increased by adding the squared features (p = 0.029, paired t-test). We also assessed whether the relatively poor performance of the different methods was due to the difficulty to learn a prognostic score combining 5 features from limited amounts of training samples, by assessing 
Discussion
Comparison to similar studies. Previous findings report divergent prognostic power for ITH in several pan cancer studies (15, 16, 27) . Andor et al (16) analyzed 1,165 patients across 12 cancer types from the TCGA, and found an overall prognostic power by considering all subtypes together, and suggested that this effect might be nonlinear, with a trade-off between ITH and overall survival (4).
However, the association between the number of subclones and overall survival was significant with EXPANDS, but not with PyClone results, and no significant association was detected when considering each cancer type separately, except for gliomas. This might be due to the small number of cases of each type (between 33 and 166). Morris et al. (15) patients from 11 types from the TCGA, and found significant prognostic power in 4 types using MATH score and distinct input mutation sets from different variant callers. They obtain significant prognostic association for all variant calling results in only one cancer type: UCEC, and already report some lack of robustness in the results. We have been further in testing up to 7 ITH methods with 2 alternative input mutation sets, in addition to the combination of all methods, and found no significant association, either for the same framework in all considered cancer types, nor for the same cancer type with all frameworks. We have also tested more powerful polynomial models to account for a potential nonlinear relationship, and results were inconclusive.
Considering results in details, there are discrepancies that should be discussed. For BRCA, conclusions are more discordant: Morris et al. (15) found significant results, Noorbakhsh et al. (27) did not, and in more specialized studies like METABRIC (49), significant association was found when considering only the upper and lower quartile of MATH score for ER+ tumors. For BLCA, contradictory conclusions were also drawn, as previous studies (15, 16) found no prognostic power and we have with some ITH methods. There are several explanations: each study considered a distinct subset of patients, with a distinct pipeline for calling mutations and measure ITH. This instability with respect to patient selection has been confirmed by our study. All of those studies, including ours, observed ITH prognostic relevance in HNSC. Good prognostic power for HNSC and BLCA might be an indication that the importance of ITH for cancer aetiology differs across cancer types.
Can we truly measure ITH?. Beyond the question of the prognostic power of ITH, our results challenge the very fact that ITH can be measured accurately with one WES sample per patient.
Up to 30 methods have been developed to tackle ITH detection and quantification from NGS data in tumor samples, and new ones are still being developed (53, 54) . This analysis has focused on relatively early but among the most widely used ITH methods in order to provide valuable insight on the degree of reliability of provided results. Indeed results presented here show that there is a very weak correlation between results obtained with different methods on the same patients.
Another source of inconsistency is that ITH methods rely on results from previous analysis steps, in particular variant calling. Indeed, all ITH methods rely on the distribution of SNV frequencies, in association or not with structural variants (also called by a variety of dedicated methods). This has already been discussed by Noorbakhsh et al. (27) for MATH score computation. We show here that this issue is not limited to the MATH score. Some authors have suggested that being very restrictive in variant calling, even resorting to targeted deep sequencing to experimentally validate SNVs (8), would exhibit less noisy results. Here we have not observed any evidence that ITH methods estimated more robust results with a restricted input mutation set (i.e. the public mutation set in this study). Overall, lack of agreement between the different ITH measures is a real concern, indicating again that ITH is probably not very accurate. A similar conclusion was recently and independently reached by (55) .
Beyond the methods used for ITH inference, the data might also be questioned. Being able to measure ITH to one sample WES with moderate sequencing depth is tempting for future clinical application where the cost and the inconvenience of multiple samples for patients should be limited (5) . However, more complex experimental settings have allowed more convincing findings in the field of tumor evolution (56, 57) , and it may be necessary to further evaluate lack of accuracy due to undersampling from the whole tumor or to use of WES instead of WGS, and the impact of sequencing depth. A recent and broad analysis of ITH with one WGS sample per patient (17) partially answers as the authors could detect ITH in almost every patient, and conduct interesting further analyses as they had confidence in the robustness of ITH estimates. Most published methods are able to account for multiple samples from the same patient, either sampled at different times or from different regions of the tumor. However, for extension to WGS analysis, our work highlights limitations with respect to the computation time for high numbers of mutation as input.
Association with survival, link with other variables. Part of this work relies on the hypothesis that higher association with patient survival is a sign of higher accuracy. We have already mentioned some technical issues associated with the setting of one sample WES per patient, as even without measure issues, ITH might just be under-represented in the sample compared to the whole tumor.
Another limitation is that this does not represent a dynamic measure. For instance a tumor can be clonal because it is not very aggressive, or on the contrary this might be the result of a selective sweep after a phase of new clonal expansion. Moreover, several authors discuss the consequences and the interplay of the presence of distinct subclonal populations, in terms of cooperation (58) (59) (60) , competition (61, 62), or even neutral evolution (63, 64) . Hence, the same level of ITH might uncover very diverse situations, and may not be a prognostic factor by itself.
Besides, ITH is likely to be influenced and to interplay with other external factors including tumor micro-environment, immune response, nutrient availability. Recent work has tried to set a full framework for analysis including many factors (65) . However, in the case of the TCGA, not all those variables are measurable, but some might be included in further work. In this line of thought, earlier results exhibited correlation of ITH with other factors like CNA abundance, sample purity, immune infiltration (15, 49, 50, 66) . Our results show that the strength (and even direction in the case of CNA abundance and mutation load) of correlation between those factors and ITH varies between the different tested ITH measures. This again calls for further and more detailed analysis, as results show ambiguity and lack of robustness.
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